Weiss Multi Strategy Advisers LLC decreased its stake in shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 50.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 30,000 shares of the biopharmaceutical company’s stock after selling 30,205 shares during the period. Weiss Multi Strategy Advisers LLC’s holdings in Intra-Cellular Therapies were worth $342,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Quantbot Technologies LP boosted its holdings in shares of Intra-Cellular Therapies by 5,520.7% during the 3rd quarter. Quantbot Technologies LP now owns 4,609 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 4,527 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth about $142,000. Creative Planning bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth about $228,000. Citigroup Inc. boosted its holdings in shares of Intra-Cellular Therapies by 19.7% during the 4th quarter. Citigroup Inc. now owns 22,585 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 3,719 shares during the period. Finally, First Trust Advisors LP bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth about $274,000. 68.20% of the stock is owned by institutional investors and hedge funds.

Several analysts recently commented on the stock. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a report on Thursday, December 20th. ValuEngine upgraded shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Friday, March 1st. BidaskClub cut shares of Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Canaccord Genuity set a $31.00 price objective on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research note on Wednesday, December 12th. Finally, Royal Bank of Canada lifted their price objective on shares of Intra-Cellular Therapies from $35.00 to $37.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 12th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $28.20.

Shares of Intra-Cellular Therapies stock opened at $12.04 on Friday. Intra-Cellular Therapies Inc has a twelve month low of $10.21 and a twelve month high of $23.64. The stock has a market capitalization of $716.52 million, a price-to-earnings ratio of -4.24 and a beta of 1.41.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.16. Equities analysts expect that Intra-Cellular Therapies Inc will post -4.05 earnings per share for the current fiscal year.

In other Intra-Cellular Therapies news, EVP Michael Halstead sold 3,108 shares of Intra-Cellular Therapies stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $12.42, for a total value of $38,601.36. Following the completion of the sale, the executive vice president now owns 24,757 shares in the company, valued at approximately $307,481.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sharon Mates sold 17,478 shares of Intra-Cellular Therapies stock in a transaction dated Wednesday, January 2nd. The stock was sold at an average price of $11.09, for a total transaction of $193,831.02. Following the completion of the sale, the chief executive officer now owns 1,156,185 shares of the company’s stock, valued at approximately $12,822,091.65. The disclosure for this sale can be found here. Insiders sold a total of 113,209 shares of company stock valued at $1,301,080 in the last quarter. Corporate insiders own 17.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Intra-Cellular Therapies Inc (ITCI) Shares Sold by Weiss Multi Strategy Advisers LLC” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/intra-cellular-therapies-inc-itci-shares-sold-by-weiss-multi-strategy-advisers-llc/2912151.html.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Featured Article: Sell-Side Analysts

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.